Dan Wildman
Dan Wildman, in addition to being a Board member, is a Strategic Advisor to PanTher Therapeutics. In this role Dan applies his expertise and decades of experience to advancing the clinical development program for PanTher’s lead program, PTM-101, and selecting and prioritizing other Sagittari™ platform product candidates. A seasoned executive with more than 35 years of experience in the MedTech industry, Dan is President of Wildman Ventures, LLC. He also currently serves as a member of the Board of Directors or as a Strategic Advisor for several early-stage organizations and publicly-held companies.
Prior to joining PanTher Therapeutics, Dan led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, where he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $2.0B in revenue and continues to be one of the fastest-growing companies in Johnson & Johnson’s medical device portfolio.
Laura Indolfi
Laura Indolfi, PhD, is Co-Founder and Chief Executive Officer. Based on foundational technology she invented in the labs at Massachusetts Institute of Technology (MIT) and Harvard Medical School, she has led PanTher’s business and scientific progress to create its proprietary Sagittari™ drug-development platform, a revolutionary technology for the local administration of cancer therapeutics to treat solid tumors. Under her leadership, the company has advanced its lead drug candidate, PTM-101, from preclinical R&D studies to clinical trials for the treatment of pancreatic cancer. Laura has raised equity and grant funding for PanTher since its inception in 2016 and built an experienced leadership team to guide the company’s success.
Laura has been recognized for her entrepreneurial accomplishments by being named a TED Fellow, one of 21 people chosen annually as the most disruptive and transformative change-makers in the world. Prior to founding PanTher Therapeutics, Laura was a postdoctoral associate at the Harvard-MIT Institute for Medical Engineering and Science and served as an entrepreneur-in-residence at the Massachusetts General Hospital Cancer Center.
She holds a PhD in Biomaterials and MS and BS degrees in Materials Science and Engineering from the University of Naples Federico II in Italy.
John Edwards
John Edwards is the Executive Chairman of the Board of Directors. John has over 35 years of experience in discovery, development, and global commercialization of biopharmaceuticals.
Prior to joining PanTher Therapeutics, John was involved with 10 FDA approved biologics and 8 biotech companies with successful exits. Most recently John was CEO and Executive Chair at Abcuro where he built the leadership team, raised $100M in financing, and successfully advanced the lead program from a preclinical stage asset to program now in a registrational clinical trial. Previously John was CEO at Verseau Therapeutics and Executive Chair at Tilos Therapeutics, where in less than two years he helped advance Tilos from founding to acquisition in 2019 by Merck. During 2019, two other preclinical-stage companies John helped build also had successful exits for investors (Exonics and Siamab). In addition, as Executive Chair, John helped lead the growth of F-star from a discovery-stage company to a leading clinical stage developer of bispecific antibodies, raising over $200M in non-dilutive capital, as well as completing several asset-based M&A transactions. As COO, John played a lead role at Adnexus, where the company went from start-up to a $450M acquisition by BMS within 4 years. He then continued as President of the company for next 3 years, working within BMS during the early days of immuno-oncology. John was Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, during which time he built what has become a >$1B global pharmaceutical business in hematology. He started his career in R&D as one of the first employees at Genzyme.
John received his MBA from Boston University and his BS in Chemical Engineering from the University of Massachusetts at Amherst.
Leslie Sloan
Leslie S. Sloan, PhD, is SVP of Development and Operations at PanTher Therapeutics. As seasoned global executive, Leslie has demonstrated a proven ability to drive execution and delivery of drug development programs.
Her broad professional experience includes executive leadership, strategic and operational program and portfolio leadership, BLA/NDA submissions and approvals, and R&D strategy and execution across multiple therapeutic areas (metabolic disease, oncology, cardiovascular) and modalities (small molecules, peptides, biologics). Leslie and her teams have been instrumental to 15 successful new or supplemental market authorization submissions in the US, EU, and Asia. Leslie is an effective leader who fosters cross-functional, empowered teams and develops people, resulting in a track record of hiring and developing talented, collaborative, and successful global teams.
Prior to joining PanTher Therapeutics, Leslie was the Chief Operating Officer of Aeglea Biotherapeutics, a human enzyme therapeutics company. During her time at Aeglea, she oversaw portfolio programs from discovery through clinical development to achieve scientific, medical, and financial objectives. Previously, Leslie held several global leadership roles at Ipsen and Pfizer. While at Ipsen, she provided strategic and operational leadership for a global R&D portfolio focused on cancer, neuroscience, and rare diseases. She also delivered cross-functional leadership for clinical program teams, spanning from IND enabling through Ph1, Ph2, and Ph3 phases of development and life cycle management. Leslie holds PhD and MS degrees in Bioorganic Chemistry from Yale University and a BS in Chemistry and Medical Biology from Southeastern Oklahoma State University.
Dan Wildman
Dan Wildman, in addition to being a Board member, is a Strategic Advisor to PanTher Therapeutics. In this role Dan applies his expertise and decades of experience to advancing the clinical development program for PanTher’s lead program, PTM-101, and selecting and prioritizing other Sagittari™ platform product candidates. A seasoned executive with more than 35 years of experience in the MedTech industry, Dan is President of Wildman Ventures, LLC. He also currently serves as a member of the Board of Directors or as a Strategic Advisor for several early-stage organizations and publicly-held companies.
Prior to joining PanTher Therapeutics, Dan led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, where he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $2.0B in revenue and continues to be one of the fastest-growing companies in Johnson & Johnson’s medical device portfolio.
Darshana Zaveri
Darshana Zaveri is a Founder and Managing Partner of Catalyst Health Ventures (CHV). She is actively involved in all aspects of fund management including investments and capital raising and has led several investments in the medical device, women’s health and diagnostics markets.
She led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive and Rejoni. She currently (or previously) represents CHV on the Boards of each of these companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women).
Darshana received an MPA from Harvard University, an MA in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.
